High-yield mAbs Manufacturing Platform Approach

• Mabion Biologics CDMO has developed an integrated mAbs manufacturing platform tailored for high-yield monoclonal antibody production.
• The platform combines proprietary cell line development technologies with optimized upstream and downstream processes. This end-to-end approach supports efficient therapeutic antibody manufacturing from early development through commercial scale.

Manufacturing Platform for mAbs Production

A contemporary mAbs manufacturing platform integrates cell line development, upstream and downstream processing, analytical control, and regulatory alignment into a harmonized framework. In monoclonal antibody production, platform creation reduces development timelines while ensuring process robustness across multiple molecules. The biologics manufacturing platform concept enables rapid progression from gene to GMP-compliant drug substance.

Process standardization across different antibodies subclasses allows the mAbs manufacturing platform to minimize molecule-specific risks. By maintaining consistent critical process parameters and critical quality attributes, monoclonal antibody production benefits from reduced variability and accelerated comparability assessments. This standardization is a hallmark of advanced biologics contract manufacturing organizations.

Quality by Design principles are embedded within the platform architecture. Risk assessments, design space definition, and control strategy implementation ensure that therapeutic antibody manufacturing meets global regulatory expectations. Such a science-driven biologics manufacturing platform approach enhances process understanding and lifecycle management.¹

Yield Optimization and Critical Process Parameters in mAbs Manufacturing Platform

High titer achievement in monoclonal antibody production depends on the interplay between genetic construct design, cell metabolism, and bioprocess control. The monoclonal antibody manufacturing platform is engineered to maximize volumetric productivity while maintaining product quality attributes such as glycosylation profile, aggregation level, and charge variants. Yield optimization is integrated with quality assurance.

Critical process parameters significantly impact cell growth and productivity. Advanced process analytical technologies and real-time monitoring tools are used in monoclonal antibody manufacturing to maintain process stability. Multivariate data analysis enables predictive control and supports consistent recombinant protein production.²

Scale-up from laboratory to commercial bioreactors requires careful tech transfer. The drug substance manufacturing platform incorporates scalable bioreactor configurations and validated scale-down models to ensure performance translation. In biologics contract manufacturing, such scalability is essential for seamless transition to clinical level.

Upstream Improvements in Recombinant Protein Production

Central to therapeutic antibody manufacturing is the use of optimized mammalian expression systems, most commonly CHO cell lines, engineered for stable recombinant protein production. Platform host cell lines are selected based on genetic stability, productivity, and product quality consistency. The integration of predefined media systems and feeding strategies supports predictable scale-up in monoclonal antibody manufacturing.

Media development and feed optimization are key contributors to enhanced biologic drug development. Chemically defined media systems reduce variability and support regulatory compliance in therapeutic antibody manufacturing. Feed strategies are optimized to control nutrient supply, minimize metabolic waste accumulation, and sustain high cell density cultures.³

Intensified bioprocessing approaches, including high-density fed-batch systems, are increasingly integrated into biologics manufacturing platform. These technologies increase space-time yield and enable flexible facility utilization.⁴

Downstream Bioprocessing Improvements in mAbs Manufacturing Platform

Downstream development within a mAbs manufacturing platform is designed to achieve high recovery titer while ensuring stringent impurity clearance.

Protein A affinity chromatography remains the primary capture step in monoclonal antibody production, delivering high selectivity and purity. Resin selection and cycle optimization significantly influence overall process economics. Subsequent polishing steps, including ion exchange chromatography and hydrophobic interaction chromatography, are configured within a platform template. These operations remove host cell proteins, DNA, aggregates, and charge variants, ensuring compliance with therapeutic antibody manufacturing standards. Process intensification strategies reduce buffer consumption and processing time.^5,6

Viral clearance validation is an essential component of biologics manufacturing platform. Low pH viral inactivation and nanofiltration steps are integrated into the downstream design to meet regulatory requirements. The mAbs manufacturing platform incorporates validated viral safety strategies aligned with global guidelines.⁷

Mabion’s Solution for Robust mAbs Manufacturing

Our biologics manufacturing strategy emphasizes scalability, regulatory compliance, and process robustness. Standardized unit operations and validated analytical methods enable rapid process transfer and technology implementation. The platform is designed to accommodate diverse monoclonal antibody formats while maintaining consistent recombinant protein production performance.

Process characterization and validation are conducted using a science-based framework aligned with international regulatory expectations. Our expertise in monoclonal antibody manufacturing ensures reliable lifecycle management. Such technical depth strengthens company’s position in biologics contract manufacturing. Through continuous improvement and technology upgrades, Mabion’s manufacturing platform evolves to incorporate process intensification, digitalization, and sustainability principles. By combining scientific expertise with scalable infrastructure, Mabion Biologics CDMO delivers high-yield, quality-driven mAbs manufacturing platform solutions.

FAQ

Prepared by:

Jakub Knurek

Marketing Specialist

j.knurek@mabion.eu

Jakub Knurek

Marketing Specialist

Jakub Knurek is a marketing and business development expert specializing in CDMO operations with scientific and biopharmaceutical background. During the COVID-19 pandemic, he contributed to the development of the Novavax protein vaccine. As a side project, he runs his own pharma company.

As the author of numerous articles, he is recognized as an important voice of the younger generation of scientists. He is a member of Mabion’s representation at industry trade shows, including Central European BioForum 2026, Eurobiotech Congress 2026, BIO International Convention 2025 in Boston, 2nd Global Biologics India 2025 in Hydrabad, CPHI 2024 in Milan, CPHI 2023 in Barcelona, Life Sciences Baltics 2023 in Vilnius.

He actively participates in academic, business and industry discussions, such as the “Building the Future Pharma Workforce” panel at CPHI Milan 2024 or “Biotech in Translation: How to Tell the Story of Innovation” at Central European BioForum 2026.

Piotr Ciesielski

Process Engineer, Team Leader

p.ciesielski@mabion.eu

Piotr Ciesielski

Process Engineer, Team Leader

Piotr Ciesielski has been part of the company since 2019 and serves as a Team Leader and Process Engineer, specializing in upstream bioprocessing. His work centers on bioreactor-based cell culture, particularly in single-use stirred tank and orbital shaken bioreactors. He plays an active role in implementing new technologies and validating manufacturing processes, contributing to projects related to process scale-up and the production of materials for clinical and commercial applications.

References

1. Wohlenberg OJ, Kortmann C, Meyer KV, Schellenberg J, Dahlmann K, Bahnemann J, Scheper T, Solle D. Optimization of a mAb production process with regard to robustness and product quality using quality by design principles. Eng Life Sci. 2022; 22(7): 484-494.
2. Das TK, Narhi LO, Sreedhara A, Menzen T, Grapentin C, Chou DK, Antochshuk V, Filipe V. Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy. J Pharm Sci. 2020; 109(1): 116-133.
3. Knurek J. Upstream Development for High Yield Biologics Production. Mabion Science Hub. 2025.
4. Olin M, Wolnick N, Crittenden H, Quach A, Russell B, Hendrick S, Armstrong J, Webster T, Hadley B, Dickson M, Hodgkins J, Busa K, Connolly R, Downey B. An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers. Biotechnol Prog. 2024; 40(2): e3410.
5. Matte A. Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. Int J Mol Sci. 2022; 23(15): 8663.
6. Hummel J, Pagkaliwangan M, Gjoka X, Davidovits T, Stock R, Ransohoff T, Gantier R, Schofield M. Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales. Biotechnol J. 2019; 14(2): e1700665.
7. Ajayi OO, Cullinan JL, Basria I, Fuentes-Arias M, Osuna-Najarro A, Johnson S, Faison T, Lute S. Analysis of Virus Clearance for Biotechnology Manufacturing Processes from Early to Late Phase Development. PDA J Pharm Sci Technol. 2025; 79(3): 252-273.

If you are interested in our manufacturing platform services, please do not hesitate to contact us. Our standardized, scalable approach supports reliable therapeutic antibody manufacturing from early development to commercial supply. We provide the scientific expertise and manufacturing infrastructure needed to reduce risk and shorten timelines. Accelerate your drug development with our integrated mAbs manufacturing platform.